IFNB1 Protein (AA 22-182, C-Term)

Catalog No. ABIN2666971

This Recombinant IFNB1 protein is produced in HEK-293 Cells.

Quick Overview for IFNB1 Protein (AA 22-182, C-Term) (ABIN2666971)

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Protein Type: Recombinant

Origin: Mouse

Source: HEK-293 Cells

Application: Western Blotting (WB), ELISA

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE prior to lyophilization.

Product Details

Protein Characteristics: C-Term, AA 22-182

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.,Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Prior to use, reconstitute the lyophilized powder with 0.2 mLof PBS containing a carrier protein (e.g., 1 % BSA, protease free), pH 7.4. Re-cap vial, vortex. Allow the reconstituted standard to sit at room temperature for 15 minutes, vortex again to mix completely. The reconstituted standard stock solution can be aliquoted into polypropylene vials and stored at -70 °C for up to one month.

Buffer: Lyophilized in sterile-filtered PBS, pH 7.2, containing 1 % BSA.

Handling Advice: Use a manual defrost freezer and avoid repeated freeze thaw cycles.

Storage: 4 °C

Storage Comment: Upon receipt, store unopened vials between 2°C and 8°C immediately and use within 12 months from date of receipt.

Expiry Date: 12 months

Target Details

Target: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Alternative Name: IFN-beta

Background: Interferon-β is a member of the type I interferon class. Type I IFNs are involved in the innate immune system, being released non-specifically during the early stage of infection in response to stimuli such as viruses, dsRNA, LPS, and bacterial components. Once secreted by virus-infected or activated cells, they bind to the IFNα/β receptor (IFNAR), which is found on almost all cell types, and, via the JAK-STAT pathway, induce the expression of hundreds of IFN-stimulated genes (ISGs). While the function of many of these proteins remains to be elucidated, a hallmark of type I IFNs is their anti-viral activities, both general and specific against particular viruses. Type I IFNs also regulate cell growth and apoptosis, and exert various immunomodulatory and inflammatory effects. As such, they are also clinically relevant, both as therapeutics and as targets of inhibition for the treatment of various autoimmune diseases and cancer. Mouse IFN-β is a ~20 kD monomeric glycoprotein. It has 50 % amino acid sequence homology with mouse IFN-α, its closest related protein, and 62 % homology with human IFN-β. IFN-β is currently the therapeutic of choice for treating multiple sclerosis.

Molecular Weight: The 175 amino acid recombinant protein has a predicted molecular mass of approximately 21.2 kDa. The DTT-reduced and non-reduced protein migrates at approximately 36 kDa by SDS-PAGE. The N-terminal amino acid is Ile.

Pathways: JAK-STAT Signaling, TCR Signaling, TLR Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Autophagy, Inflammasome